Wall Street Analysts Believe Aura Biosciences (AURA) Could Rally 119.61%: Here's is How to Trade
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences Q3 EPS $(0.29) Beats $(0.37) Estimate
Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences: A Pivotal Trial Engineered With Room To Spare
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Is Aura Investments (TASE:AURA) Fully Valued As Mixed Earnings And A New Dividend Stir Interest?
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval
Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement With Jefferies
HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences to Participate in Upcoming Investor Conferences
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.